Evidence Explorer · MS-N053

Expressive writing for symptoms and physical quality of life in renal cell carcinoma

Family: Psychological and narrative supportive care
Clinical question: Can brief expressive writing improve symptoms or quality of life in people with renal cell carcinoma?
Evidence label: Modest positive single-trial signal with important null outcomes.

Evidence at a glance

• Benefit: At 10 months, expressive writing was associated with better overall symptom burden and physical quality of life than neutral writing.
• Certainty: One randomized trial; several prespecified patient-reported outcomes were null.
• Risk: Temporary emotional activation is possible; writing is not a substitute for psycho-oncology or crisis care.
• Cancer control: Not studied.

What was studied

A randomized trial enrolled 277 adults with stage I–IV renal cell carcinoma. Participants completed four expressive-writing sessions about cancer-related thoughts and feelings or neutral-writing sessions, with assessment at baseline and 1, 4, and 10 months.

What the evidence shows

At 10 months, the expressive-writing group had lower MD Anderson Symptom Inventory scores (P=.003) and higher SF-36 physical-component scores (P=.019). There were no between-group differences in fatigue, depression, sleep disturbance, or the SF-36 mental-component score. About 28% of the sample had stage IV disease; 41% were women and mean age was 58.

What this does not show: The trial does not establish tumor response, delayed progression, or longer survival. It also does not show broad benefit across all emotional and physical outcomes.

Limits and uncertainty

• Single disease-specific trial, with patient-reported outcomes and no participant blinding.
• Benefits emerged at a later time point and were not consistent across all outcomes.
• Absolute effect sizes and a prespecified clinically meaningful threshold were not verified for this appraisal.
• Participants willing to complete emotionally focused writing may differ from people who decline it.

Safety and practical context

Some people find disclosure relieving; others feel worse during or after writing. It is reasonable to stop if distress escalates. Persistent depression, trauma symptoms, suicidal thoughts, or severe anxiety should be assessed by a qualified clinician.

Questions for the care team

• Would structured writing feel supportive or burdensome right now?
• Is there access to psycho-oncology support if difficult material surfaces?
• Which symptom or quality-of-life outcome matters, and when will it be reassessed?
• Could untreated pain, sleep problems, depression, or treatment toxicity better explain current symptoms?

Sources

• Randomized renal-cell-carcinoma trial (PMID 24470003)
• Full text (PMCID PMC3927735)
• ClinicalTrials.gov NCT00505310

Identifiers: PMID 24470003; PMCID PMC3927735; NCT00505310
Last literature search: October 17, 2026
Record appraised: October 17, 2026

Educational information, not personal medical advice. Decisions about symptoms, supplements, movement, or psychological care during cancer treatment should be made with the oncology team.